Zygomycosis: Reemergence of an old pathogen

Clinical Infectious Diseases

Volumn 39, Issue 4, 2004, Pages 588-590

  Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; DRUG USE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION RISK; MEDICAL LITERATURE; MUCORMYCOSIS; NOTE; PRIORITY JOURNAL;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HEMATOLOGIC DISEASES; HUMANS; MUCORALES; ORGAN TRANSPLANTATION; RHIZOPUS; RISK FACTORS; ZYGOMYCOSIS; ZYGOMYCOTA;

EID: 4344627134     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422729     Document Type: Note

References (19)

1. Ibrahim AS, Edwards JE, Filler SG. Zygomycosis. In: Dismukes WE, Pappas PG, Sobel JD, eds. Medical mycology. Oxford Press: New York, 2003:241-51.
2. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem-cell transplant patients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7 (in this issue).
3. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2.
4. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant patients receiving voriconazole. Clin Infect Dis (in press).
5. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
6. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72:78-89.
7. van Burik JA, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidasis. an autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246-54.
8. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30:851-6.
9. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
10. Agger WA, Maki DG. Mucormycosis: a complication of critical care. Arch Intern Med 1978; 138:925-7.
11. Abzug MJ, Gardner S, Glode MP, et al. Helioport-asociated nosocomial mucormycosis. Infect Control Hosp Epidemiol 1992; 13: 325-6.
12. Hagan EA, Stern H, Porter D, et al. High rate of invasive fungal infections following non-myeloablative allogeneic transplantation. Clin Infect Dis 2003; 36:9-15.
13. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
14. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-33.
15. Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriquez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole. J Antimicrob Chemother 2001; 48:919-21.
16. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
17. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infection after marrow transplantation: a prospective randomized study. J Infect Dis 1995; 171:1545-52.
18. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prohylaxis in allogeneic hematopoietic stem cell transplant recipients. Ann Intern Med 2003; 138:705-13.
19. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112:369-79.